Molecular basis and current strategies of therapeutic arginine depletion for cancer
- PMID: 26913960
- DOI: 10.1002/ijc.30051
Molecular basis and current strategies of therapeutic arginine depletion for cancer
Abstract
Renewed interest in the use of therapeutic enzymes combined with an improved knowledge of cancer cell metabolism, has led to the translation of several arginine depletion strategies into early phase clinical trials. Arginine auxotrophic tumors are reliant on extracellular arginine, due to the downregulation of arginosuccinate synthetase or ornithine transcarbamylase-key enzymes for intracellular arginine recycling. Engineered arginine catabolic enzymes such as recombinant human arginase (rh-Arg1-PEG) and arginine deiminase (ADI-PEG) have demonstrated cytotoxicity against arginine auxotrophic tumors. In this review, we discuss the molecular events triggered by extracellular arginine depletion that contribute to tumor cell death.
Keywords: arginine deiminase; arginine deprivation; recombinant human arginase.
© 2016 UICC.
Similar articles
-
Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment.Int J Mol Sci. 2023 Jun 26;24(13):10668. doi: 10.3390/ijms241310668. Int J Mol Sci. 2023. PMID: 37445845 Free PMC article. Review.
-
Arginine deprivation in cancer therapy.Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):78-82. doi: 10.1097/MCO.0000000000000122. Curr Opin Clin Nutr Metab Care. 2015. PMID: 25474015 Review.
-
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.Oncotarget. 2010 Aug;1(4):246-51. doi: 10.18632/oncotarget.135. Oncotarget. 2010. PMID: 21152246 Free PMC article. Review.
-
Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination.Cancer Lett. 2021 Apr 1;502:58-70. doi: 10.1016/j.canlet.2020.12.041. Epub 2021 Jan 8. Cancer Lett. 2021. PMID: 33429005 Review.
-
The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.Expert Opin Investig Drugs. 2014 Nov;23(11):1517-29. doi: 10.1517/13543784.2014.934808. Epub 2014 Jun 26. Expert Opin Investig Drugs. 2014. PMID: 24965808 Review.
Cited by
-
Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment.Int J Mol Sci. 2023 Jun 26;24(13):10668. doi: 10.3390/ijms241310668. Int J Mol Sci. 2023. PMID: 37445845 Free PMC article. Review.
-
The Role of Pi, Glutamine and the Essential Amino Acids in Modulating the Metabolism in Diabetes and Cancer.J Diabetes Metab Disord. 2020 Aug 19;19(2):1731-1775. doi: 10.1007/s40200-020-00566-5. eCollection 2020 Dec. J Diabetes Metab Disord. 2020. PMID: 33520860 Free PMC article. Review.
-
PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults.Front Oncol. 2024 Jan 31;14:1296576. doi: 10.3389/fonc.2024.1296576. eCollection 2024. Front Oncol. 2024. PMID: 38357205 Free PMC article.
-
Arginine-dependent immune responses.Cell Mol Life Sci. 2021 Jul;78(13):5303-5324. doi: 10.1007/s00018-021-03828-4. Epub 2021 May 26. Cell Mol Life Sci. 2021. PMID: 34037806 Free PMC article. Review.
-
Therapeutic potential of arginine deprivation therapy for gliomas: a systematic review of the existing literature.Front Pharmacol. 2024 Aug 22;15:1446725. doi: 10.3389/fphar.2024.1446725. eCollection 2024. Front Pharmacol. 2024. PMID: 39239650 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous